The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50
Abstract
We have previously reported methicillin-resistant Staphylococcus aureus clinical strains, Mu50 and Mu3, representing two categories of vancomycin resistance: Mu50 representing vancomycin-resistant S. aureus (VRSA) with MICs > or = 8 mg/L, and Mu3 representing hetero-VRSA with MICs < or = 4 mg/L using standard MIC determination methods. The mechanisms of vancomycin resistance in these strains were investigated. These strains did not carry the enterococcal vancomycin-resistance genes, vanA, vanB, or vanC1-3, as tested by PCR using specific primers. However, both strains produced three to five times the amount of penicillin-binding proteins (PBPs) 2 and 2' when compared with vancomycin-susceptible S. aureus control strains with or without methicillin resistance; the amounts of PBP2 produced in Mu3 and Mu50 were comparable to those in the vancomycin-resistant S. aureus mutant strains selected in vitro. Incorporation of 14C-labelled Nacetyl-glucosamine into the cell was three to 20 times increased in Mu50 and Mu3, and release of the radioactive cell wall material was increased in Mu3 (and also in Mu50, though to a lesser extent), compared with control strains. The amounts of intracellular murein monomer precursor in these strains were three to eight times greater than those found in control strains. Transmission electron microscopy showed a doubling in the cell wall thickness in Mu50 compared with the control strains. Mu3 did not show obvious cell wall thickening. These data indicate that activated synthesis and an increased rate of cell wall turnover are common features of Mu3 and Mu50 and may be the prerequisite for the expression of vancomycin resistance in S. aureus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Self-citationHiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Self-citationNoble, W. C., Virani, Z., & Cree, R. G. A. (1992) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1992.tb05089.x · Cited by 627
Emergence of Vancomycin Resistance in Coagulase-Negative Staphylococci
Schwalbe, R. S., Stapleton, J. T., & Gilligan, P. H. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161507 · Cited by 584
Liu, F.-T., Zinnecker, M., Hamaoka, T., & Katz, D. H. (1979) · Biochemistry · doi:10.1021/bi00571a022 · Cited by 460
Characterization of glycopeptide-resistant enterococci from U.S. hospitals
Clark, N. C., Cooksey, R. C., Hill, B. C., Swenson, J. M., & Tenover, F. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2311 · Cited by 395
Utsui, Y., & Yokota, T. (1985) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.28.3.397 · Cited by 365
de Jonge, B. L., Chang, Y. S., Gage, D., & Tomasz, A. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49903-1 · Cited by 315
Hiramatsu, K. (1995) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1995.tb02239.x · Cited by 206
Cited by
Mechanisms of Antimicrobial Resistance in Bacteria
Tenover, F. C. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.03.011 · Cited by 1,682
Antimicrobial resistance: the example of Staphylococcus aureus
Lowy, F. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18535 · Cited by 1,445
Katayama, Y., Ito, T., & Hiramatsu, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1549-1555.2000 · Cited by 1,038
Iwase, T., Uehara, Y., Shinji, H., Tajima, A., Seo, H., Takada, K., Agata, T., & Mizunoe, Y. (2010) · Nature · doi:10.1038/nature09074 · Cited by 991
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Ito, T., Ma, X. X., Takeuchi, F., Okuma, K., Yuzawa, H., & Hiramatsu, K. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2637-2651.2004 · Cited by 675
Mechanisms of antimicrobial resistance in bacteria
Tenover, F. C. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.219 · Cited by 637
Antibiotic treatment expands the resistance reservoir and ecological network of the phage metagenome
Modi, S. R., Lee, H. H., Spina, C. S., & Collins, J. J. (2013) · Nature · doi:10.1038/nature12212 · Cited by 542
Kuroda, M., Kuroda, H., Oshima, T., Takeuchi, F., Mori, H., & Hiramatsu, K. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03599.x · Cited by 512
Cell Wall Thickening Is a Common Feature of Vancomycin Resistance in Staphylococcus aureus
Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M.-N., Ploy, M.-C., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.5-14.2003 · Cited by 492
Antibiotic Resistance and the MRSA Problem
Vestergaard, M., Frees, D., & Ingmer, H. (2019) · Microbiology Spectrum · doi:10.1128/microbiolspec.gpp3-0057-2018 · Cited by 490
Vancomycin resistance in Staphylococcus aureus
Appelbaum, P. C., & Bozdogan, B. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.004 · Cited by 485
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
Modes and Modulations of Antibiotic Resistance Gene Expression
Depardieu, F., Podglajen, I., Leclercq, R., Collatz, E., & Courvalin, P. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00015-06 · Cited by 427
The emergence of antibiotic resistance by mutation
Woodford, N., & Ellington, M. J. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01492.x · Cited by 417
“The precise molecular mechanism has not been defined, but thickening of the cell wall is a consistent phenotypic consequence [95,168–170].”
BackgroundIncreasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Vancomycin-Resistant Staphylococcus aureus Isolate from a Patient in Pennsylvania
Tenover, F. C., Weigel, L. M., Appelbaum, P. C., McDougal, L. K., Chaitram, J., McAllister, S., Clark, N., Killgore, G., O'Hara, C. M., Jevitt, L., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.275-280.2004 · Cited by 370
Antimicrobial resistance: the example of Staphylococcus aureus
Lowy, F. D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318535 · Cited by 369
Sakoulas, G., Eliopoulos, G. M., Moellering, R. C., Wennersten, C., Venkataraman, L., Novick, R. P., & Gold, H. S. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1492-1502.2002 · Cited by 364
New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin
Zhanel, G. G., Calic, D., Schweizer, F., Zelenitsky, S., Adam, H., Lagacé-Wiens, P. R. S., Rubinstein, E., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2010) · Drugs · doi:10.2165/11534440-000000000-00000 · Cited by 352
Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen
Stryjewski, M. E., & Corey, G. R. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit613 · Cited by 334
Tiwari, H. K., & Sen, M. R. (2006) · BMC Infectious Diseases · doi:10.1186/1471-2334-6-156 · Cited by 335
Utaida, S., Dunman, P. M., Macapagal, D., Murphy, E., Projan, S. J., Singh, V. K., Jayaswal, R. K., & Wilkinson, B. J. (2003) · Microbiology · doi:10.1099/mic.0.26426-0 · Cited by 326
Liu, C., & Chambers, H. F. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3040-3045.2003 · Cited by 321
Cui, L., Murakami, H., Kuwahara-Arai, K., Hanaki, H., & Hiramatsu, K. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2276-2285.2000 · Cited by 318
Self-citationGlycopeptide antibiotics: Back to the future
Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R., & Cooper, M. A. (2014) · The Journal of Antibiotics · doi:10.1038/ja.2014.111 · Cited by 303
Vancomycin Resistance in Staphylococci
Srinivasan, A., Dick, J. D., & Perl, T. M. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.3.430-438.2002 · Cited by 285
Mechanism of action of oritavancin and related glycopeptide antibiotics
Allen, N. (2003) · FEMS Microbiology Reviews · doi:10.1016/s0168-6445(02)00144-4 · Cited by 276
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
Metadata
- Authors
- Hanaki, H.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-08-01
- Volume
- 42
- Issue
- 2
- Pages
- 199-209
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2124205716
- Cited by
- 366
- References
- 23
- FWCI
- 16.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.